Dermira sweeps PhIII psoriasis studies for Cimzia as rivals threaten another entry
Dermira has wrapped the third and final psoriasis study of Cimzia, which the biotech says cleared the final hurdles in the lead up to an FDA filing later this year.
This latest study — triggered by a development deal Dermira struck with UCB in 2014 for US and EU rights to the rheumatoid arthritis drug — gathered up fresh evidence of Cimzia’s effectiveness in psoriasis, including a beat over Enbrel with a 400 mg dose at week 12 and noninferiority over Enbrel at 200 mg. The primary endpoint was the week 12 PASI 75 score on clearance, and the anti-TNF therapy came in at 66.7% for patients receiving the 400 mg dose every two weeks and 61.3.% for patients receiving the CIMZIA 200 mg dose every two weeks, compared to 5.0% for patients receiving placebo.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.